Nano-inspired technologies offer unique opportunities to treat numerous diseases by using
therapeutic peptides. Therapeutic peptides have attractive pharmacological profiles and can be manufactured
at relatively low costs. The major advantages of using a nanodelivery approach comprises
significantly lower required dosages compared to systemic delivery, and thus reduced toxicity and
immunogenicity. The combination of therapeutic peptides with delivery peptides and nanoparticles or
small molecule drugs offers systemic treatment approaches, instead of aiming for single biological
targets or pathways. This review article discusses exemplary state-of-the-art nanosized delivery systems
for therapeutic peptides and antibodies, as well as their biochemical and biophysical foundations
and emphasizes still remaining challenges. The competition between using different nanoplatforms,
such as liposome-, hydrogel-, polymer-, silica nanosphere-, or nanosponge-based delivery systems is
still “on” and no clear frontrunner has emerged to date.
Keywords: Peptide drug, nanodelivery, physiological barriers, toxicity, immunogenicity, therapeutic peptides.
Rights & PermissionsPrintExport